The instinct on seeing a 2021 grant is to count twenty years from 2021. That instinct is wrong, and US11090367B2 - "Restoration of tumor suppression using mRNA-based delivery system," issued August 17, 2021 to The Brigham and Women's Hospital - is a useful object lesson in why expiry math starts with the filing date, not the issue date.
A U.S. utility patent's term is twenty years from the earliest non-provisional application to which it claims priority, not from the day it issues. A platform-method patent like this one, which may sit in a priority chain reaching back years before the 2021 grant, can therefore have substantially less than twenty years of life remaining at issue. Reading the term off the issue date overstates the exclusivity.
The patent's character matters for what the term protects. The CPC tags - A61K 38/465 (enzyme-delivery preparations), A61K 9/5146 / 9/5153 (nanoparticle formulations), A61P 35/00 (antineoplastic use) - describe a method of delivering mRNA to restore a tumor-suppressor function. That is a method-and-formulation claim, the kind whose value is the platform application, not a single product.
For exclusivity analysis, two corrections always apply. First, anchor the term to the priority date via the patent's continuity data, not the issue date. Second, check for any patent-term adjustment (PTA) that USPTO delay may have added back - PTA can extend the nominal term, partly offsetting a long prosecution. Neither can be read off the front page alone.
The broader point for platform IP is that issue-date-based expiry estimates are systematically optimistic for the holder and misleading for a competitor planning entry. The real horizon lives in the priority chain and the term adjustments - and a 2021 grant on a method that was filed years earlier may clear sooner than its issue date suggests.